
Dihexa
Potential Benefits
- Preclinical studies suggest potent promotion of new synapse formation
- Animal models indicate potential cognitive enhancement in both healthy and impaired subjects
- May cross the blood-brain barrier when taken orally based on animal data
- Research suggests potential for neurodegenerative disease applications
- Acts through the HGF/c-Met receptor system, a pathway involved in neural development
Recommended Starting Dose
10-20 mg orally or 5-10 mg subcutaneously (highly experimental; no established human dose)
Based on published research protocols. Not a prescription.
Dosing Protocol
No established human dosing protocol. Anecdotal reports describe oral doses of 10-20 mg daily or sublingual administration. Some use subcutaneous injection. Given the lack of human safety data, extreme caution is warranted. This is among the most experimental compounds on this list.
DOSING INFORMATION DISCLAIMER: Any dosing information, protocols, or ranges discussed on this site are drawn from published research studies and clinical literature. They are presented for educational reference only and must not be used as self-medication guidance.
Expected Timeline
Phase 1
Anecdotal reports vary widely. Some users report cognitive changes within days, though this has not been validated in any clinical study.
Research Status
The regulatory status of peptides can change at any time. Verify current FDA classification and legal status in your jurisdiction before seeking medical consultation about this compound.
Potential Side Effects
- No published human safety data
- Potent biological activity raises concerns about unpredictable effects
- Theoretical risk of promoting unwanted cell growth (HGF/c-Met pathway is implicated in some cancers)
- Long-term effects in any species are not well-characterized
- Unregulated compound with significant quality control concerns
More in Cognitive

Selank
Selank
Selank is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is derived from the naturally occurring immunomodulatory peptide tuftsin with an added Pro-Gly-Pro sequence for stability. It is approved in Russia as an anxiolytic and nootropic nasal spray.

Semax
Semax
Semax is a synthetic heptapeptide derived from a fragment of adrenocorticotropic hormone (ACTH 4-10) with an added Pro-Gly-Pro C-terminal tripeptide for metabolic stability. Developed in Russia, it is approved there for conditions including stroke recovery, cognitive disorders, and peptic ulcers. It is administered intranasally.

PE-22-28
PE-22-28 (Spadin analog)
PE-22-28 is a synthetic heptapeptide derived from spadin, which itself is a fragment of the sortilin propeptide. It acts as an antagonist of the TREK-1 potassium channel, a validated target for antidepressant activity. Research suggests it may have rapid-onset antidepressant-like effects in animal models, acting within days rather than weeks.
Medical Disclaimer
EDUCATIONAL CONTENT ONLY: The peptide information presented on this page is compiled from published scientific literature, peer-reviewed research, and publicly available clinical data. It is provided strictly for educational purposes and does not constitute medical advice, an endorsement of any specific peptide, or a recommendation for treatment. Many peptides discussed on this site have not received FDA approval for human therapeutic use. Some may be under active regulatory review or subject to restrictions on compounding under FDA Section 503A and 503B frameworks. The regulatory status of individual peptides can change at any time. Readers should verify the current legal status of any peptide in their jurisdiction before pursuing further information or consultation. If you are considering peptide therapy, seek guidance from a licensed physician or healthcare provider who specializes in peptide-based treatments and operates within applicable federal and state regulations.